Determining the Lymphokine Activated Killer (LAK) Cytotoxicity Present in Patients Undergoing Interleukin-2 Therapy

Loma Linda University (LLU)

Status: Terminated

Conditions: Melanoma; Kidney Cancer

Study type: Observational

Funder types: Other

Identifiers

NCT01068470

59210

Details and patient eligibility

About

Therapy with Interleukin-2 stimulates lymphocytes in humans to become Lymphokine-activated Killer cells (LAK). This study will determine if these killer cells are able to kill certain standard cell-lines in the laboratory.

Full description

Blood samples will be taken from patients undergoing outpatient Interleukin-2 therapy to measure the LAK cytotoxicity at baseline, after 1 cycle of therapy and 2 months later. The LAK cytotoxicity assay will be a standard colorimetric assay that measures lactic dehydrogenase release from lysed cells.

Enrollment: 11 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients must be undergoing Interleukin-2 therapy under the care of physicians at Loma Linda University Cancer Center
• Patients must sign and give written informed consent in accordance with institutional and federal guidelines

Exclusion criteria

• Patients not undergoing Interleukin-2 therapy under the care of physicians at Loma Linda University Cancer Center

Trial design

11 participants in 1 patient group

patients with melanoma or kidney cancer